-
Signature
-
/s/ John Faurescu, attorney-in-fact for Dr. Kaye
-
Stock symbol
-
CYTK
-
Transactions as of
-
Dec 1, 2025
-
Transactions value $
-
-$1,487,436
-
Form type
-
4
-
Date filed
-
12/2/2025, 09:18 AM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Kaye Edward M. MD |
Director |
350 OYSTER POINT BLVD, SOUTH SAN FRANCISCO |
/s/ John Faurescu, attorney-in-fact for Dr. Kaye |
2025-12-02 |
0001522780 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CYTK |
Common Stock |
Options Exercise |
$100K |
+8.06K |
+80.83% |
$12.40 |
18K |
Dec 1, 2025 |
Direct |
|
| transaction |
CYTK |
Common Stock |
Options Exercise |
$285K |
+20K |
+110.86% |
$14.25 |
38K |
Dec 1, 2025 |
Direct |
|
| transaction |
CYTK |
Common Stock |
Sale |
-$1.87M |
-28.1K |
-73.77% |
$66.72 |
9.98K |
Dec 1, 2025 |
Direct |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
CYTK |
Non-Qualified Stock Option (Right to Buy) |
Options Exercise |
$0 |
-8.06K |
-100% |
$0.00 |
0 |
Dec 1, 2025 |
Common Stock |
8.06K |
$12.40 |
Direct |
F1 |
| transaction |
CYTK |
Non-Qualified Stock Option (Right to Buy) |
Options Exercise |
$0 |
-20K |
-100% |
$0.00 |
0 |
Dec 1, 2025 |
Common Stock |
20K |
$14.25 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: